New research calls for a health equity lens in commercial tobacco product regulation

Innovation
Jul.19.2022

University of Minnesota School of Public Health Assistant Professor Dana Mowls Carroll co-authored a recent commentary in Preventive Medicine on how commercial tobacco policies contribute to inequities, including the unequal and unjust burden of tobacco-related disease and death among racialized populations.

The researchers explained that policies allow the continued sale of menthol cigarettes — especially via targeted marketing — that increase the risk of commercial tobacco use among Black or African American (B/AA) and Indigenous American adults. At the same time, policies banning e-cigarette flavors to prevent young people from starting to vape have received considerable attention. These policies disproportionately benefit white youth, whose  e-cigarette use is higher compared to B/AA youth. Although youth e-cigarette use prevention is critical, the level of support, urgency and publicity for banning e-cigarette flavors exceeds that for banning menthol cigarettes, furthering inequities in how regulation benefits various groups.

 

The writers assert that equitable opportunities for a healthy life can no longer be afterthoughts or secondary aims for policymakers, and call for a health equity lens in commercial tobacco product regulation and provide individual and system-level recommendations that put health equity at the forefront of regulation and research.

New research calls for a health equity lens in commercial tobacco product regulation

Their recommendations include:

The Food and Drug Administration — which regulates commercial tobacco products at the national level — should address health equity directly while evaluating regulations and prioritizing research that examines how regulations, or lack thereof, may increase or decrease commercial tobacco-related health inequities experienced by B/AA and Indigenous American groups.

Community engagement is critical and public health professionals must be prepared to do this well. This approach can be used to authentically engage with populations at greatest risk for tobacco-related disease and ensure their voices and wisdom are prioritized during policy development and implementation.

More B/AA and Indigenous American tobacco regulatory science researchers should be mentored, recruited and supported in their training.

This work must start with understanding the roots of inequities. All researchers must educate themselves about the cultural and historic contexts in which their academic and community institutions exist and their impacts on B/AA and Indigenous communities.

“Striving for the highest possible standard of health for all people means that we must educate ourselves on the true roots of inequities, particularly racism, and identify public health approaches and policies that are anti-racist,” said Carroll. “I am interested in how populations that bear the greatest smoking-related burdens benefit to a lesser extent from, or can even be harmed by, the implementation or lack of tobacco-related policies when compared with socially privileged populations.”

 

This research was supported by the National Institute on Drug Abuse of the National Institutes of Health (NIH), by the National Institute on Minority Health and Health Disparities of the NIH and the Center for Tobacco Products of the U.S. Food and Drug Administration. 

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

AIR Expects to Complete CAEP Business Combination in Q2 2026 and List on Nasdaq
AIR Expects to Complete CAEP Business Combination in Q2 2026 and List on Nasdaq
AIR Limited and Cantor Equity Partners III announced that the F-4 registration statement related to their proposed business combination was declared effective by the U.S. Securities and Exchange Commission on April 22, 2026. Under the arrangement first announced on Nov. 7, 2025, the combined company, AIR Global PLC, is intended to list on Nasdaq in the United States under the ticker “AIIR.”
Apr.24 by 2FIRSTS.ai
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group reported its results for the year ended December 31, 2025. Revenue was RMB 1.496 billion, down about 9.5% from RMB 1.653 billion in 2024. Gross profit was RMB 377.1 million, with a gross margin of 25.2%, and the group recorded a net loss of RMB 1.000 billion for the year.
Mar.24 by 2FIRSTS.ai
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
New Zealand Vape Company Alt Becomes Government Partner After Suing Over Nicotine Limits
Health NZ signed a NZD 500,000 contract with New Zealand-owned vape company Alt NZ Limited in December 2025 for its free vape kit programme for smokers, with more than 7,000 kits distributed so far.
Mar.23 by 2FIRSTS.ai
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR Resolves Global Dispute Over "ELF" Trademark with VPR Brands LP
ELFBAR announces global settlement with VPR Brands LP over "ELF" trademark dispute, covering major markets like US, Canada, UK.
Apr.01 by 2FIRSTS.ai
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem US, the maker and seller of Zone nicotine pouches, has voluntarily dismissed its lawsuit against the U.S. Food and Drug Administration, which it had accused of unfairly delaying its market application.
Mar.25 by 2FIRSTS.ai